Lineagen competitors

Dr. Brian Alexander was named Chief Executive Officer of Foundation Medicine in March 2021. He previously served as the company’s Chief Medical Officer since 2019, and is a practicing radiation oncologist specializing in neuro-oncology at Dana-Farber/Brigham and Women’s Cancer Center, and a Senior Lecturer at Harvard Medical School. Since joining the company in September 2018 as a Senior Vice President of Clinical Development, Dr. Alexander has played a pivotal leadership role in Foundation Medicine’s decision insights strategy, helping oncologists, both in community and academic settings, determine the right treatment, at the right time, for each unique patient. Under his leadership, Foundation Medicine’s medical team has expanded its molecular tumor board program to include over 90 leading oncology centers globally, launched a cross-functional genomics and health disparities effort, and has developed hundreds of studies and publications to advance the clinical utility of genomic profiling. Dr. Alexander was the founding director of the Program in Regulatory Science at the Dana-Farber Cancer Institute and the Harvard/MIT Center for Regulatory Science. He also co-founded the Global Coalition for Adaptive Research, a non-profit organization focused on clinical trial innovations to accelerate the discovery and development of cures for patients with rare and deadly diseases, and served as chair of the FDA/Project Datasphere task force on external control arms. Dr. Alexander is an affiliated researcher at the MIT Laboratory for Financial Engineering and affiliated faculty of the Harvard Kennedy School Healthcare Policy Program. He was named to Boston Magazine’s “Top Doctors List” in 2019, 2020, and 2021. Previously, Dr. Alexander served as a White House fellow and Special Assistant to the Secretary of Veterans Affairs, where he helped prepare the VA for the transition of administrations, worked to develop a public reporting system for quality, and served as a health policy advisor to the Secretary. Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. He was also a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education. Dr. Alexander’s research interests focus on innovations in clinical evidence generation to support the development of therapeutics, biomarkers, and novel endpoints. He co-authored a book titled “Diagnostic Test Interpretation and Reasoning Under Uncertainty,” detailing the use of Bayesian approaches to clinical decision-making. Dr. Alexander was the founding principal investigator of INSIGhT, a multi-institutional genomic biomarker-based Bayesian adaptively randomized trial for patients with glioblastoma. He is the recipient of the Burroughs-Wellcome Innovations in Regulatory Science Award for his work applying such approaches to clinical trial design. Dr. Alexander received his B.A. from Kalamazoo College, M.D. from the University of Michigan Medical School, and M.P.H. from the Harvard School of Public Health. He completed his training in radiation oncology at the Harvard Radiation Oncology Program.

Prior to joining Genocea,Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Before that, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

John 'Chip' Scarlett is a Co-Founder at Covance and Board Member at CYTOMX THERAPEUTICS, INC. and is based in Menlo Park, California. He has worked as Board Member at GERON CORP, Board Member at Chiasma Inc, and Adjunct Assistant Professor of Medicine at Hospital of the University of Pennsylvania. John works or has worked as Various Positions at Mcneil Pharmaceuticals and Dir:Medical Research & Svcs at Mcneil Pharmaceuticals. He studied at University of Colorado Boulder between 1980 and 1982, University of Chicago - The Pritzker School of Medicine between 1973 and 1977, and Earlham College between 1969 and 1973.

Kevin S. Wilson has been Heska's Chief Executive Officer and President since March 31, 2014. He previously served as the President and Chief Operating Officer since February 2013. Mr. Wilson is a founder, member and officer of Cuattro, LLC. Since 2008, he has been involved in developing technologies for radiographic imaging with Cuattro, LLC and including as a founder of Cuattro Software, LLC, Cuattro Medical, LLC and Cuattro Veterinary, LLC. Mr. Wilson served on the board of various private, non-profit, and educational organizations from 2005 to 2011. He was a founder of Sound Technologies, Inc., a diagnostic imaging company, in 1996. After Sound Technologies, Inc. was sold to VCA Antech, Inc. in 2004, Mr. Wilson served as Chief Strategy Officer for VCA Antech, Inc. until 2006. Mr. Wilson attended Saddleback College.

Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.

Douglas 'Doug' Ingram is a CEO and President at SAREPTA THERAPEUTICS, INC.; Board Member at SAREPTA THERAPEUTICS, INC.; and Board Member at Relay Therapeutics Inc and is based in Irvine, California. He has worked as Assistant General Counsel at Actavis, President at Actavis, and Board Member at Volcom. Douglas works or has worked as BOARD MEMBER at Allergan Foundation and Board Member at Pacific Life. He studied at James E Rogers College of Law until 1988, Arizona State University between 1980 and 1985, and University of Arizona.

Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers. Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies’ sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer). Mr. Sanders earned a Bachelor’s business degree with an emphasis in marketing from Memphis State University.